Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease.
Freudenberg
Folke
F
Wintergerst
Uwe
U
Roesen-Wolff
Angela
A
Albert
Michael H
MH
Prell
Christine
C
Strahm
Brigitte
B
Koletzko
Sibylle
S
Ehl
Stephan
S
Roos
Dirk
D
Tommasini
Alberto
A
Ventura
Alessandro
A
Belohradsky
Bernd H
BH
Seger
Reinhard
R
Roesler
Joachim
J
Güngör
Tayfun
T
D017668:Age of Onset; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002648:Child; D004359:Drug Therapy, Combination; D017353:Gene Deletion; D006105:Granulomatous Disease, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D019255:NADPH Oxidases / Q000172:deficiency* / Q000235:genetics; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D013256:Steroids; D019255:NADPH Oxidases; C060505:neutrophil cytosolic factor 1; D014740:Vidarabine; C024352:fludarabine